文章：

激素替代疗法与绝经后新发或既往子宫内膜异位症患者各类癌症风险研究

Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis

原文发布日期：16 February 2024

DOI: 10.3390/cancers16040809

类型: Article

开放获取: 是

英文摘要：

This study examined the impact of hormone replacement therapy (HRT) on the occurrence of various cancers in postmenopausal women with de novo or a history of endometriosis. In the datasets for ten cancers (cervical, uterine, ovarian, breast, colon, gastric, liver, lung, pancreatic, and thyroid), women who received HRT (the HRT group) and those who did not (the control group) were selected by a 1:1 matching with those who met the study criteria. In the dataset for each cancer, the incidence of each cancer was very low (0.2% to 1.5% in the HRT group and 0.2% to 1.3% in the control group). The duration of HRT was 1.3 ± 2.1 years. After adjusting for co-variables, HRT was a significant risk factor for uterine cancer (p< 0.05). However, the risk of liver cancer decreased significantly with duration of HRT (p< 0.05). Moreover, combined estrogen and progesterone decreased the risks of liver and thyroid cancers significantly (p< 0.05), and estrogen alone decreased the risks of breast and lung cancers significantly (p< 0.05). Tibolone was not associated with the risk of any of the cancers assessed. These results can help guide the use of HRT in women with de novo or a history of endometriosis.

摘要翻译： 

本研究探讨了激素替代疗法（HRT）对初发或有子宫内膜异位症病史的绝经后妇女多种癌症发生的影响。在十种癌症（宫颈癌、子宫癌、卵巢癌、乳腺癌、结肠癌、胃癌、肝癌、肺癌、胰腺癌和甲状腺癌）的数据集中，通过1:1匹配符合研究标准的妇女，分别选取接受HRT治疗组（HRT组）和未接受治疗组（对照组）。各癌症数据集中，每种癌症的发生率均较低（HRT组为0.2%至1.5%，对照组为0.2%至1.3%）。HRT治疗持续时间为1.3±2.1年。调整协变量后，HRT是子宫癌的显著危险因素（p<0.05）。然而，肝癌风险随HRT持续时间显著降低（p<0.05）。此外，雌孕激素联合治疗显著降低了肝癌和甲状腺癌的风险（p<0.05），而单纯雌激素治疗显著降低了乳腺癌和肺癌的风险（p<0.05）。替勃龙与所评估的任何癌症风险均无关联。这些结果可为初发或有子宫内膜异位症病史的妇女使用HRT提供指导。

原文链接：

Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis